Elanco Animal Health (NYSE:ELAN) Releases Q4 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its fourth quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.160-0.190 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.170-1.200 EPS.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent research reports. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and reduced their target price for the stock from $31.00 to $24.00 in a research note on Tuesday, October 20th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Elanco Animal Health Price Performance

ELAN traded up $1.95 during trading on Friday, reaching $25.63. 4,890,442 shares of the company were exchanged, compared to its average volume of 5,591,565. The company’s 50-day moving average is $23.11 and its two-hundred day moving average is $23.82. The company has a market cap of $12.81 billion, a price-to-earnings ratio of -62.38, a P/E/G ratio of 2.25 and a beta of 1.73. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health has a 12-month low of $19.40 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Friday, November 6th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Research analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Timothy Bettington sold 4,350 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the transaction, the insider directly owned 138,911 shares in the company, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Harrington acquired 5,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. This represents a 3.95% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 48,998 shares of company stock valued at $1,139,373 over the last ninety days. 1.14% of the stock is owned by insiders.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.